Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03344016 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multicenter Pheochromocytoma and Paraganglioma Evaluation

Study acronym: MUPPET
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 2035 to Nov 1, 2035v3 Show 4 more changesShow less
    • Study completion date: Nov 2040 to Nov 1, 2040
    • Start date changed from estimate of Nov 2017 to Nov 1, 2017
    • Study site revised
    • Collaborators revised (6)
  2. Study title shortened, about 10 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Target population: Patients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility genes. International multicenter prospective cohort study with randomized intervention (special care follow-up vs. standard care follow-up). All patients will receive instructions about follow-up at the time point of study inclusion. Patients randomized to the standard care follow-up group will be advised to return annually for follow-up according to current routine practice (without active re-scheduling). In contrast, patients randomized to the special care follow-up group will also be advised to return annually for follow-up but these patients will be actively invited, re-scheduled and reminded by the centers to meet scheduled follow-up appointments.
Trial Details
NCT Number NCT03344016
Lead Sponsor Felix Beuschlein
Collaborators: Technische Universität Dresden, Wuerzburg University Hospital, University of Zurich, Radboud University Medical Center, Lübeck University Clinic, Ludwig-Maximilians - University of Munich
Conditions
(from sponsor)		 Pheochromocytoma, Paraganglioma
Related terms Paraganglioma, Pheochromocytoma
Enrollment 1,148 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov